Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Sympathetic control of bone mass regulated by osteopontin.

Nagao M, Feinstein TN, Ezura Y, Hayata T, Notomi T, Saita Y, Hanyu R, Hemmi H, Izu Y, Takeda S, Wang K, Rittling S, Nakamoto T, Kaneko K, Kurosawa H, Karsenty G, Denhardt DT, Vilardaga JP, Noda M.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17767-72. doi: 10.1073/pnas.1109402108.

2.

Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system.

Kondo H, Nifuji A, Takeda S, Ezura Y, Rittling SR, Denhardt DT, Nakashima K, Karsenty G, Noda M.

J Biol Chem. 2005 Aug 26;280(34):30192-200.

3.

β2-Adrenergic receptor signaling in osteoblasts contributes to the catabolic effect of glucocorticoids on bone.

Ma Y, Nyman JS, Tao H, Moss HH, Yang X, Elefteriou F.

Endocrinology. 2011 Apr;152(4):1412-22. doi: 10.1210/en.2010-0881.

4.

Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin.

Ishijima M, Rittling SR, Yamashita T, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M.

J Exp Med. 2001 Feb 5;193(3):399-404.

5.

Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual.

Kajimura D, Hinoi E, Ferron M, Kode A, Riley KJ, Zhou B, Guo XE, Karsenty G.

J Exp Med. 2011 Apr 11;208(4):841-51. doi: 10.1084/jem.20102608.

6.

PTH regulates β2-adrenergic receptor expression in osteoblast-like MC3T3-E1 cells.

Moriya S, Hayata T, Notomi T, Aryal S, Nakamaoto T, Izu Y, Kawasaki M, Yamada T, Shirakawa J, Kaneko K, Ezura Y, Noda M.

J Cell Biochem. 2015 Jan;116(1):142-8. doi: 10.1002/jcb.24953.

PMID:
25164990
8.

Osteopontin expression in co-cultures of human squamous cell carcinoma-derived cells and osteoblastic cells and its effects on the neoplastic cell phenotype and osteoclastic activation.

Teixeira LN, de Castro Raucci LM, Alonso GC, Coletta RD, Rosa AL, de Oliveira PT.

Tumour Biol. 2016 Sep;37(9):12371-12385.

PMID:
27312487
9.

Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression.

Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, Rifas L, Rittling SR, Denhardt DT, Hruska KA.

Mol Biol Cell. 2003 Jan;14(1):173-89.

10.

Regulation of the osteopontin gene by the orphan nuclear receptor NURR1 in osteoblasts.

Lammi J, Huppunen J, Aarnisalo P.

Mol Endocrinol. 2004 Jun;18(6):1546-57.

PMID:
14988426
11.
12.

Osteopontin Promotes Oncostatin M Production in Human Osteoblasts: Implication of Rheumatoid Arthritis Therapy.

Su CM, Chiang YC, Huang CY, Hsu CJ, Fong YC, Tang CH.

J Immunol. 2015 Oct 1;195(7):3355-64. doi: 10.4049/jimmunol.1403191.

13.

Dose effects of butoxamine, a selective β2-adrenoceptor antagonist, on bone metabolism in spontaneously hypertensive rat.

Arai M, Sato T, Takeuchi S, Goto S, Togari A.

Eur J Pharmacol. 2013 Feb 15;701(1-3):7-13. doi: 10.1016/j.ejphar.2012.12.016.

PMID:
23321373
14.

Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts.

Ono N, Nakashima K, Rittling SR, Schipani E, Hayata T, Soma K, Denhardt DT, Kronenberg HM, Ezura Y, Noda M.

J Biol Chem. 2008 Jul 11;283(28):19400-9. doi: 10.1074/jbc.M800005200.

15.

Osteopontin deficiency suppresses high phosphate load-induced bone loss via specific modulation of osteoclasts.

Koyama Y, Rittling SR, Tsuji K, Hino K, Salincarnboriboon R, Yano T, Taketani Y, Nifuji A, Denhardt DT, Noda M.

Endocrinology. 2006 Jun;147(6):3040-9.

PMID:
16513836
16.

Regulation of osteopontin expression in osteoblasts.

Sodek J, Chen J, Nagata T, Kasugai S, Todescan R Jr, Li IW, Kim RH.

Ann N Y Acad Sci. 1995 Apr 21;760:223-41.

PMID:
7785896
17.
18.

Osteopontin deficiency increases bone fragility but preserves bone mass.

Thurner PJ, Chen CG, Ionova-Martin S, Sun L, Harman A, Porter A, Ager JW 3rd, Ritchie RO, Alliston T.

Bone. 2010 Jun;46(6):1564-73. doi: 10.1016/j.bone.2010.02.014.

19.

Beta Adrenergic Receptor Stimulation Suppresses Cell Migration in Association with Cell Cycle Transition in Osteoblasts-Live Imaging Analyses Based on FUCCI System.

Katsumura S, Ezura Y, Izu Y, Shirakawa J, Miyawaki A, Harada K, Noda M.

J Cell Physiol. 2016 Feb;231(2):496-504. doi: 10.1002/jcp.25096.

PMID:
26192605
20.

Supplemental Content

Support Center